Аннотация
Доксорубицин (ДОКС) является одним из наиболее эффективных химиотерапевтических препаратов антрациклинового ряда, при этом его применение в клинической практике ограничено наличием ярко выраженных побочных эффектов в отношении жизненно важных органов – сердца, почек, легких, печени. На сегодняшний день отсутствуют эффективные препараты, способные снизить системное токсическое действие ДОКС. Никотинамид рибозид (НР) может рассматриваться в качестве перспективного фармакологического агента, способного обеспечивать комплексный защитный эффект от системного влияния токсических эффектов ДОКС. Целью данной работы являлась комплексная морфологическая оценка жизненно важных органов (сердце, легкие, печень, почки) крыс стока Wistar в условиях воздействия ДОКС при внутривенном введении НР в различных режимах в качестве протективного агента. Работа выполнена на 60 самцах крыс весом 283 ± 22 гр. Животные были разделены на 4 группы: интактная, контрольная (внутрибрюшинное введение ДОКС), опытные группы животных (внутрибрюшинное введение ДОКС) с превентивным и сочетанным режимом внутривенного введения НР. По окончании введения фармакологических агентов наблюдение за животными составило 2 месяца. На этапе окончания исследования у наркотизированных животных осуществляли взятие сердца, легких, печени, почек для проведения морфологических исследований. Эхокардиографический анализ осуществлялся с целью подтверждения развития кардиотоксических эффектов ДОКС. В условиях воздействия ДОКС наибольшие морфологические изменения наблюдались в сердце, почках и легких. Используемые схемы введения НР обеспечивали протективный эффект в отношении жизненно важных органов, при этом наиболее выраженное защитное действие НР наблюдалось при использовании превентивного режима.
Литература
Hussen NH, Hasan AH, Muhammed GO, Yassin AY (2023) Anthracycline in Medicinal Chemistry: Mechanism of Cardiotoxicity, Preventive and Treatment Strategies. Curr Org Chem 1–15. https://doi.org/10.2174/1385272827666230423144150
Schirone L, D’ambrosio L, Forte M, Genovese R, Schiavon S, Spinosa G, Iacovone G, Valenti V, Frati G, Sciarretta S (2022) Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay. Cells 11:1–16. https://doi.org/10.3390/cells11132000
Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S (2019) Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol 96:219–232. https://doi.org/10.1124/mol.119.115725
Ma W, Wei S, Zhang B, Li W (2020) Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. Front Cell Dev Biol 8:1–17. https://doi.org/10.3389/fcell.2020.00434
Li N, Jiang W, Wang W, Xiong R, Wu X, Geng Q (2021) Ferroptosis and its emerging roles in cardiovascular diseases. Pharmacol Res 166:105466. https://doi.org/10.1016/j.phrs.2021.105466
Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L, Szabó C, Pacher P (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol - Hear Circ Physiol 296:1466–1483. https://doi.org/10.1152/ajpheart.00795.2008
Christidi E, Brunham LR (2021) Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis 12:. https://doi.org/10.1038/s41419-021-03614-x
Prasanna PL, Renu K, Valsala Gopalakrishnan A (2020) New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci 250:117599. https://doi.org/10.1016/j.lfs.2020.117599
Alhowail AH, Bloemer J, Majrashi M, Pinky PD, Bhattacharya S, Yongli Z, Bhattacharya D, Eggert M, Woodie L, Buabeid MA, Johnson N, Broadwater A, Smith B, Dhanasekaran M, Arnold RD, Suppiramaniam V (2019) Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation. Toxicol Mech Methods 29:457–466. https://doi.org/10.1080/15376516.2019.1600086
Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA, Karuppusamy I (2018) Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci 200:26–30. https://doi.org/10.1016/j.lfs.2018.03.023
Fujimura T, Yamagishi SI, Ueda S, Fukami K, Shibata R, Matsumoto Y, Kaida Y, Hayashida A, Koike K, Matsui T, Nakamura KI, Okuda S (2009) Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant 24:1397–1406. https://doi.org/10.1093/ndt/gfn659
Ramadan R, Faour D, Awad H, Khateeb E, Cohen R, Yahia A, Torgovicky R, Cohen R, Lazari D, Kawachi H, Abassi Z (2012) Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome. Nephrol Dial Transplant 27:2231–2241. https://doi.org/10.1093/ndt/gfr581
Aljobaily N, Viereckl MJ, Hydock DS, Aljobaily H, Wu TY, Busekrus R, Jones B, Alberson J, Han Y (2021) Creatine alleviates doxorubicin-induced liver damage by inhibiting liver fibrosis, inflammation, oxidative stress, and cellular senescence. Nutrients 13:1–15. https://doi.org/10.3390/nu13010041
Owumi SE, Lewu DO, Arunsi UO, Oyelere AK (2021) Luteolin attenuates doxorubicin-induced derangements of liver and kidney by reducing oxidative and inflammatory stress to suppress apoptosis. Hum Exp Toxicol 40:1656–1672. https://doi.org/10.1177/09603271211006171
Owumi SE, Nwozo SO, Arunsi UO, Oyelere AK, Odunola OA (2021) Co-administration of Luteolin mitigated toxicity in rats’ lungs associated with doxorubicin treatment. Toxicol Appl Pharmacol 411:115380. https://doi.org/10.1016/j.taap.2020.115380
Podyacheva E, Toropova Y (2022) SIRT1 activation and its effect on intercalated disc proteins as a way to reduce doxorubicin cardiotoxicity. Front Pharmacol 13:1–23. https://doi.org/10.3389/fphar.2022.1035387
Guven C, Sevgiler Y, Taskin E (2018) Mitochondrial Dysfunction Associated with Doxorubicin. Mitochondrial Dis. https://doi.org/10.5772/intechopen.80284
Santos-Alves E, Rizo-Roca D, Marques-Aleixo I, Coxito P, Martins S, Guimarães JT, Oliveira PJ, Torrella JR, Magalhães J, Ascensão A (2019) Physical exercise positively modulates DOX-induced hepatic oxidative stress, mitochondrial dysfunction and quality control signaling. Mitochondrion 47:103–113. https://doi.org/10.1016/j.mito.2019.05.008
Podyacheva E, Toropova Y (2021) Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects. Nutrients 13:3435. https://doi.org/10.3390/nu13103435
Zheng D, Zhang Y, Zheng M, Cao T, Wang G, Zhang L, Brockman J, Zhong H, Fan G, Peng T, Sciences M, Health L, Centre S, Physiology S (2019) Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity. Clin Sci (Lond) 133:1505–1521. https://doi.org/10.1042/CS20181022.Nicotinamide
Mazumder S, Barman M, Bandyopadhyay U, Bindu S (2020) Sirtuins as endogenous regulators of lung fibrosis: A current perspective. Life Sci 258:118201. https://doi.org/10.1016/j.lfs.2020.118201
Liu ZH, Zhang Y, Wang X, Fan XF, Zhang Y, Li X, Gong Y sheng, Han LP (2019) SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition. Biomed Pharmacother 118:. https://doi.org/10.1016/j.biopha.2019.109227
Masri S, Rigor P, Cervantes M, Ceglia N, Sebastian C, Xiao C, Roqueta-Rivera M, Deng C, Osborne TF, Mostoslavsky R, Baldi P, Sassone-Corsi P (2014) Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. Cell 158:659–672. https://doi.org/10.1016/j.cell.2014.06.050
Cai J, Liu Z, Huang X, Shu S, Hu X, Zheng M, Tang C, Liu Y, Chen G, Sun L, Liu H, Liu F, Cheng J, Dong Z (2020) The deacetylase sirtuin 6 protects against kidney fibrosis by epigenetically blocking β-catenin target gene expression. Kidney Int 97:106–118. https://doi.org/10.1016/j.kint.2019.08.028
Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F (2019) Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol 10:1–9. https://doi.org/10.3389/fmicb.2019.01050
Podyacheva E, Semenova N, Zinserling V, Mukhametdinova D, Goncharova I, Zelinskaya I, Sviridov E, Martynov M, Osipova S, Toropova Y (2022) Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy. Int J Mol Sci 23:1–19. https://doi.org/10.3390/ijms232113096
Toropova YG, Pechnikova NA, Zelinskaya IA, Zhuravsky SG, Kornyushin O V., Gonchar AI, Ivkin DY, Leonova Y V., Karev VE, Karabak IA (2018) Nicotinamide riboside has protective effects in a rat model of mesenteric ischaemia-reperfusion. Int J Exp Pathol 99:304–311. https://doi.org/10.1111/iep.12302
Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG (2021) Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician. Front Pharmacol 12:1–12. https://doi.org/10.3389/fphar.2021.670479
Podyacheva E, Shmakova T, Kushnareva E, Onopchenko A, Martynov M, Andreeva D, Toropov R, Cheburkin Y, Levchuk K, Goldaeva A, Toropova Y (2022) Modeling Doxorubicin-Induced Cardiomyopathy With Fibrotic Myocardial Damage in Wistar Rats. Cardiol Res 13:339–356. https://doi.org/10.14740/cr1416
Ahmad F, Tomar D, Aryal A C S, Elmoselhi AB, Thomas M, Elrod JW, Tilley DG, Force T (2020) Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. Biochim Biophys Acta - Mol Basis Dis 1866:165609. https://doi.org/10.1016/j.bbadis.2019.165609
Shahzadi SK, Marzook H, Qaisar R, Ahmad F (2022) Nicotinamide riboside kinase-2 inhibits JNK pathway and limits dilated cardiomyopathy in mice with chronic pressure overload. Clin Sci (Lond) 136:181–196. https://doi.org/10.1042/CS20210964
Jiang R, Zhou Y, Wang S, Pang N, Huang Y, Ye M, Wan T, Qiu Y, Pei L, Jiang X, Huang Y, Yang H, Ling W, Li X, Zhang Z, Yang L (2019) Nicotinamide riboside protects against liver fibrosis induced by CCl4 via regulating the acetylation of Smads signaling pathway. Life Sci 225:20–28. https://doi.org/10.1016/j.lfs.2019.03.064
Pham TX, Bae M, Kim MB, Lee Y, Hu S, Kang H, Park YK, Lee JY (2019) Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis. Biochim Biophys Acta - Mol Basis Dis 1865:2451–2463. https://doi.org/10.1016/j.bbadis.2019.06.009
Ikewuchi CC, Ikewuchi JC, Ifeanacho MO (2021) Aqueous leafextracts of Chromolaena odorata and Tridax procumbens attenuated doxorubicin-induced pulmonary toxicity in Wistar rats. Biotechnologia 102:387–398. https://doi.org/10.5114/BTA.2021.111096
Grant MKO, Seelig DM, Sharkey LC, Choi WSV, Abdelgawad IY, Zordoky BN (2019) Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. PLoS One 14:1–19. https://doi.org/10.1371/journal.pone.0212486
Xiang C, Yan Y, Zhang D (2021) Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro. J Pharmacol Sci 145:6–15. https://doi.org/10.1016/j.jphs.2020.10.002
Demir F, Demir M, Aygun H (2020) Evaluation of the protective effect of edaravone on doxorubicin nephrotoxicity by [99mTc]DMSA renal scintigraphy and biochemical methods. Naunyn Schmiedebergs Arch Pharmacol 393:1383–1390. https://doi.org/10.1007/s00210-020-01832-2
Soltani Hekmat A, Chenari A, Alipanah H, Javanmardi K (2021) Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats. BMC Pharmacol Toxicol 22:1–11. https://doi.org/10.1186/s40360-021-00494-x
Zhang J, Li Y, Liu Q, Huang Y, Li R, Wu T, Zhang Z, Zhou J, Huang H, Tang Q, Huang C, Zhao Y, Zhang G, Jiang W, Mo L, Zhang J, Xie W, He J (2021) Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells. Hepatology 73:1140–1157. https://doi.org/10.1002/hep.31418
Hong YA, Kim JE, Jo M, Ko GJ (2020) The role of sirtuins in kidney diseases. Int J Mol Sci 21:1–21. https://doi.org/10.3390/ijms21186686
Cetrullo S, D’Adamo S, Tantini B, Borzì RM, Flamigni F (2015) MTOR, AMPK, and sirt1: Key players in metabolic stress management. Crit Rev Eukaryot Gene Expr 25:59–75. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2015012975